Hi, mooers! 👋
The AI world holds its breath! $NVIDIA (NVDA.US)$ will release its Q4 FY2025 earnings on February 26, just before the market opens.  As the AI kingpin faces heightened scrutiny amid market volatility, will it defy expectations again? This is your chance to earn rewards and gain insights by predicting the opening price. Let’s get into it! 🎉
Stay Ahead of the Game
Subscribe to @Moo Live for real-time updates, expert analysis, and t...

Not even a swath of deals that sent $Intel (INTC.US)$ shares advancing more than 5% is enough to deter the bears.
In the first two hours of trading on Tuesday, speculators and/or investors spent millions of dollars on bearish option positions against the semiconductor company even as the stock rallied. The trades were posted after the chipmaker announced it struck a multibillion-dollar deal with $Amazon (AMZN.US)$ and c...

Market acting like a new pandemic happened. Ffs this overreaction. Watch this V shape recover!!
$NVIDIA (NVDA.US)$
$Super Micro Computer (SMCI.US)$
$Microsoft (MSFT.US)$
$Alphabet-A (GOOGL.US)$
$Palantir (PLTR.US)$
$Tesla (TSLA.US)$
$Apple (AAPL.US)$
$Meta Platforms (META.US)$
$Amazon (AMZN.US)$

Hello Mooers!
Do you know all of the $Futu Holdings Ltd (FUTU.US)$ MooMoo merchandise that has been with us since we began trading on the MooMoo platform?
No? It's alright , because today we're going over some of them.
Without further ado, let's begin!
Back in 2021, Mooers could exchange their MooMoo points for baseball hats (*1), astronaut MooCows (*2), and even life-sized MooElephants (*3).
A year later, in 2022, more products became availab...

$Novavax (NVAX.US)$
The undeniable power in the vaccine market: Novavax
In today's ever-changing medical care field, finding investment opportunities with long-term growth potential is crucial. Novavax, a biotechnology company based in the USA, has stood out due to its groundbreaking advancements in vaccine development. Especially amid the increasing global demand for COVID-19 vaccines, Novavax has demonstrated its significant role in this critical area. Additionally, the company's technological platform and research capabilities lay a solid foundation for its future growth.
Innovation-driven growth strategy
Novavax's core strength lies in its innovative nanoparticle vaccine technology, which has been applied in the development of its COVID-19 vaccine - NVX-CoV2373. This vaccine has not only demonstrated high efficacy in protection, but has also received emergency use authorization in multiple countries globally. In addition, Novavax is developing other vaccines, including those for influenza and a combined vaccine for COVID-19 and influenza, all of which address significant market demands.
Financial stability and market opportunities
From a financial perspective, Novavax has successfully improved its financial position through strategic fund management and enhancing its supply chain efficiency. The company's recent quarterly financial report has shown growth in revenue and cost...